The administration yesterday issued an interim final rule requiring health plans to begin submitting annual information next year on prescription drug coverage and spending, including the most frequently dispensed and costliest drugs, and information on prescription drug rebates and their impact on premiums and out-of-pocket spending. The rule also requires health plans and issuers to report on total spending for health care services by type (e.g., hospital care, primary care, specialty care, prescription drugs and other medical costs, including wellness services); and premium and prescription drug spending by employers versus employees. The departments of Health and Human Services, Labor and Treasury will use the data to issue biennial reports on prescription drug pricing trends and the impact of prescription drug costs on premiums and out-of-pocket costs starting in 2023. 

Related News Articles

Headline
U.S. spending on health care is projected to grow an estimated 4.2% in 2021, down from 9.7% in 2020, as spending due to the COVID-19 pandemic fell, the Centers…
Headline
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement…
News
Drug companies raised prices faster than inflation for about half of all drugs covered by Medicare between July 2019 and July 2020, according to an analysis…
Headline
Hospitals experiencing an extraordinary circumstance beyond their control affecting their ability to submit data or their performance may continue to request…
News
The Centers for Medicare & Medicaid Services Dec. 29 formally rescinded its Most Favored Nation model for Part B drugs. The model was established via…
Headline
In addition to being based on a very small sample size, a recently published study on hospital costs for clinician-administered drugs under Medicare Part B…